Soligenix receives conditional fda acceptance of proposed brand name hybryte™ for sgx301 in ctcl

Princeton, n.j., april 7, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the u.s. food and drug administration (fda) has conditionally accepted hybryte™ as the proposed brand name for sgx301 (synthetic hypericin), the company's novel first-in-class photodynamic therapy for first-line treatment of early stage cutaneous t-cell lymphoma (ctcl).
SNGX Ratings Summary
SNGX Quant Ranking